Asset Details
Do you wish to reserve the book?
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Do you wish to request the book?
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
2018
Overview
CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA (ctDNA) level may provide early response prediction, but the impact of tumor heterogeneity is unknown. Here we use plasma samples from patients in the randomized phase III PALOMA-3 study of CDK4/6 inhibitor palbociclib and fulvestrant for women with advanced breast cancer and show that relative change in
PIK3CA
ctDNA level after 15 days treatment strongly predicts PFS on palbociclib and fulvestrant (hazard ratio 3.94, log-rank
p
= 0.0013).
ESR1
mutations selected by prior hormone therapy are shown to be frequently sub clonal, with
ESR1
ctDNA dynamics offering limited prediction of clinical outcome. These results suggest that early ctDNA dynamics may provide a robust biomarker for CDK4/6 inhibitors, with early ctDNA dynamics demonstrating divergent response of tumor sub clones to treatment.
Circulating tumor DNA (ctDNA) may provide a prediction of treatment response, but could be impacted by tumor heterogeneity. Here, the authors investigate ctDNA in CDK4/6 inhibitor treatment in advanced breast cancer, finding ctDNA levels predict progression-free survival and anticipate clonal selection.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 45/77
/ Antineoplastic Agents - therapeutic use
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Cancer
/ Circulating Tumor DNA - genetics
/ Circulating Tumor DNA - metabolism
/ Class I Phosphatidylinositol 3-Kinases - genetics
/ Class I Phosphatidylinositol 3-Kinases - metabolism
/ Cyclin-Dependent Kinase 6 - genetics
/ Cyclin-Dependent Kinase 6 - metabolism
/ DNA
/ Dynamics
/ Estradiol - analogs & derivatives
/ Female
/ Humanities and Social Sciences
/ Humans
/ Mutation
/ Piperazines - therapeutic use
/ Receptors, Estrogen - genetics
/ Receptors, Estrogen - metabolism
/ Science
/ Tumors
